Capital International Ltd. CA Buys 4,357 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital International Ltd. CA increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 31.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,430 shares of the biotechnology company’s stock after purchasing an additional 4,357 shares during the period. Capital International Ltd. CA’s holdings in Sarepta Therapeutics were worth $2,241,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Louisiana State Employees Retirement System boosted its stake in shares of Sarepta Therapeutics by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after buying an additional 100 shares during the last quarter. Manchester Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares during the period. UMB Bank n.a. increased its position in shares of Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 138 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Sarepta Therapeutics by 5.1% in the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 139 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after acquiring an additional 145 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Scotiabank lowered their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Royal Bank of Canada lowered Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $161.83.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $53.79 on Friday. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25. The firm has a market capitalization of $5.22 billion, a P/E ratio of 43.03 and a beta of 0.93. The company has a fifty day simple moving average of $82.21 and a two-hundred day simple moving average of $107.88. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.